P2X Receptors and Their Pharmacology
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 33
Special Issue Editor
2. Laboratório de Avaliação e Promoção da Saúde Ambiental, Instituto Oswaldo Cruz, Av. Brasil 4365, Rio de Janeiro 21040-360, Brazil
Interests: P2X receptors; synthetic molecules; natural products; phytopharmaceuticals
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The P2X family constitutes an important class of receptors within the purinergic system. They are identified as membrane ion channels that are preferentially permeable to Na+ and K+ and with significant amounts of Ca+2 that open within milliseconds after interacting with extracellular adenosine 5'-triphosphate (ATP). The P2X2, P2X4 and especially P2X7 subtypes have exceptional abilities to increase plasma membrane permeability. The therapeutic potential of P2X family receptors has been investigated in a number of pathologies, including neuropathic pain, inflammation, depression, irritable bowel syndrome, interstitial cystitis, dysfunctional urinary bladder and cancer. In this context, studying the functioning of the P2X receptors becomes limited by the lack of selective antagonists with potent in vitro and in vivo activity in animal models and appropriate pharmacokinetic and pharmacodynamic properties in humans, which demonstrate a superior effect to the reference drug in clinical trials.
Thus, several research groups and pharmaceutical industries have invested in discovering new antagonists for P2X receptors, mainly for the P2X7 and P2X3 receptor. Additionally, several patents, case studies and clinical trials that focus on P2X receptors have increased in recent years, mainly focusing on the P2X7 receptor.
The proposed topics cover the action of new and already known antagonists in different study models, repositioned drugs, and ongoing studies of P2X receptor activity modulators. Authors are invited to submit original articles on basic research, clinical research, reviews, case studies, and other studies in this field.
Prof. Dr. Robson Xavier Faria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- compounds
- substances
- synthetic
- natural product
- inhibitor
- purinergic receptor
- ATP
- antagonista
